These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30496913)

  • 21. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens.
    Taubert M; Zander J; Frechen S; Scharf C; Frey L; Vogeser M; Fuhr U; Zoller M
    J Antimicrob Chemother; 2017 Aug; 72(8):2304-2310. PubMed ID: 28541510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linezolid dosing in critically ill patients undergoing various modalities of renal replacement therapy: a pooled population pharmacokinetic analysis.
    Liu Q; Li S; Xie F
    Int J Antimicrob Agents; 2023 Oct; 62(4):106949. PubMed ID: 37574029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.
    Roger C; Muller L; Wallis SC; Louart B; Saissi G; Lipman J; Lefrant JY; Roberts JA
    J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
    BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study.
    Xu J; Duan L; Li J; Chen F; Xu X; Lu J; Zhuang Z; Cao Y; Yuan Y; Liu X; Sun J; Zhou Q; Shi L; Tang L
    BMC Infect Dis; 2022 Aug; 22(1):667. PubMed ID: 35918657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
    Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
    Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
    Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation.
    Wu X; Tang Y; Zhang X; Wu C; Kong L
    Drug Des Devel Ther; 2018; 12():1679-1684. PubMed ID: 29928111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.
    Millard J; Pertinez H; Bonnett L; Hodel EM; Dartois V; Johnson JL; Caws M; Tiberi S; Bolhuis M; Alffenaar JC; Davies G; Sloan DJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1755-1762. PubMed ID: 29584861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
    Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
    Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
    Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
    J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.